Matrix Laboratories Limited

New Document

Financial Year 2007 - 2008

Quarter IV
(March 2008)

Quarter III
(December 2007)

Quarter II
(September 2007)

Quarter I
(June 2007)

Financial Year 2006 - 2007

Quarter IV
(March 2007)

Quarter III
(December 2006)

Quarter II
(September 2006)

Quarter I
(June 2006)
Financial Year 2005 - 2006

Quarter III
(December 2005)

Quarter II
(September 2005)

Quarter I
(June 2005)

Financial Year 2004 - 2005

Quarter IV
(March 2005)

Quarter III
(December 2004)

Quarter II
(September 2004)

Quarter I
(June 2004)

Financial Year 2003 - 2004

Quarter IV
(March 2004)

Quarter III
(December 2003)

Quarter II
(September 2003)

Quarter I
(June 2003)

Financial Year 2002 - 2003

Quarter IV
(March 2003)

Quarter III
(December 2002)

Quarter II
(September 2002)

Quarter I
(June 2002)

MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH SEPTEMBER 2004

(Rs.in Million )

Sl. No	Particulars	Quarter ended 30th September		Half Year ended 30th September		Year Ended 31st March 2004 (Un audited)
		2004 (Un Audited)	2003 (Audited)	2004 (Un Audited)	2003 ( Audited)
	Gross Sales - Exports - Domestic	1708.55 922.20 786.35	1421.17 735.04 686.13	3340.07 1836.00 1504.07	2691.44 1503.10 1188.34	5604.27 3104.02 2500.25
1	Net Sales	1624.70	1348.77	3164.67	2549.83	5327.21
2	Other Income	42.31	26.64	71.42	42.02	89.73
3	Total Expenditure a) (Increase) / Decrease in Stock b) Consumption of Raw materials c) Staff Cost d) Other Expenditure	1093.55 (37.31) 806.16 74.84 249.86	922.82 (189.81) 813.64 52.74 246.25	2149.39 (127.35) 1597.03 140.38 539.33	1734.13 (219.86) 1368.91 97.71 487.37	3544.21 (407.95) 2695.26 201.68 1055.22
4	Interest	16.34	29.12	45.10	55.66	180.07
5	Depreciation	39.61	27.72	76.68	49.22	110.45
6	Profit before Tax (1+2-3-4-5)	517.51	395.75	964.92	752.84	1582.21
7 8	Provision for Tax - Current - Deferred	39.00 59.00	50.00 25.00	69.00 69.00	75.00 50.00	148.00 85.00
9	Profit after Tax (6-7-8)	419.51	320.75	826.92	627.84	1349.21
10	Prior period adjustments including taxes	-	-	-	-	2.91
11	Profit after Tax and adjustments (9-10)	419.51	320.75	826.92	627.84	1346.30
12	Equity Capital (fully paid up Rs. 10 each)	145.54	123.03	145.54	123.03	123.03
13	Reserves excluding revaluation reserves	-	-	-	-	2169.59
14	Basic E.P.S - Not Annualised (Rs.) - Annualised (Rs.) Diluted E.P.S - Not Annualised(Rs.) - Annualised (Rs.)	28.84 115.35 28.03 112.11	26.07 104.28 26.07 104.28	59.61 119.22 57.86 115.72	51.03 102.06 51.03 102.06	- 109.47 - 107.84
15	Aggregate of Non promoters Shareholding Number of shares Percentage of Shareholding	10180885 69.98%	6375134 51.84%	10180885 69.98%	6375134 51.84%	6797134 55.27%

Notes :
1.The above unaudited results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 26th October 2004.

2. Pending completion of legal formalities, the financial results of amalgamating companies (Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited) are not included above. Diluted EPS, however is after considering the proposed equity issue to shareholders of amalgamating companies. Provision for Income tax for the year ended 31st March 2004 is computed after considering setoff and brought forward losses / allowances of the amalgamating companies.

3. Provision for tax has been estimated on prorata basis after considering various tax deductions available for the year ending 31st March 2005.

4. The activities of the Company relate to only one segment i.e. Pharmaceuticals.

5.Figures of the earlier periods, have been regrouped to conform to those of the current quarter.

6.Summary of Investor Complaints

Opening Received during
the Quarter Resolved Closing

Nil 5 5 Nil

	For and on behalf of the Board
Place : Mumbai Date : 26th October 2004	Sd/- N.PRASAD Chairman & CEO

Foote Page